EphedrineMarket, By Dosage Form (Tablets, Capsules, and Injections), By DiseaseIndication (Bronchial Asthma, Spinal Anesthesia induced Hypotension, andOthers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOthers), and By Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019- 2027
Ephedrine is a decongestant andbronchodilator, used to treat bronchospasms caused due to asthma. The medicinereduces the swelling and constricts the blood vessels in the nasal passageswhich widens the lung airways and allows the patient to breathe easily. Due tothe medicine’s central nervous system stimulatory effects, ephedrine is alsoused extensively during spinal anesthesia in order to prevent intra-operativehypotension. The medicine is available in the form of tablets, capsules andinjections.
Global Ephedrine Market –Dynamics
High prevalence of hypotensionduring spinal anesthesia is expected to propel growth of the ephedrine marketover the forecast period. For instance, according to the Columbian Journal ofAnesthesiology, 2018, incidences of hypotension during spinal anesthesia rangesfrom 1.9% to 71% globally.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3320
Moreover, launches and approvalsof ephedrine products is expected to boost the ephedrine market growth over theforecast period. For instance, in January 2017, Par Pharmaceutical, asubsidiary of Endo International plc, received approval from the U.S. Food andDrug Administration (FDA) for its new ephedrine sulfate injection, CORPHEDRA.The injection will be used to for the treatment of hypotension occurring in theprocess of spinal anesthesia.
However, restrictions onephedrine usage through regulatory authorities is expected to restrain themarket over the forecast period. For instance, since 2001, the Government ofCanada has authorized ephedrine only as a nasal decongestant with a maximumdosage of 8mg along with 32mg in a 24 hour period.
Global Ephedrine Market –Regional Insights
North America accounted for thelargest market share in 2018, owing to launches and approvals of new ephedrineproducts in the region. For instance, in March 2017, Akorn, Inc., a developerand manufacturer of generics and branded prescription pharmaceuticals, receivedthe U.S. Food and Drug Administration (FDA) approval for its New DrugApplication (NDA) for single dose ampule of an ephedrine sulfate injectionwhich is indicated for treating hypotension occurring during spinal anesthesia.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/ephedrine-market-3320
Increasing ephedrine productlaunches is expected to propel the market growth in the Europe region. Forinstance, in April 2016, Avadel Pharmaceuticals, formerly known as FlamelTechnologies, received approval from the U.S. Food and Drug Administration forAkovaz, an ephedrine sulfate injection, which will be used to treat hypotensionoccurring during anesthesia.
Moreover, high prevalence ofhypotension during spinal anesthesia in Asia Pacific is likely to drive theephedrine market over the forecast period. For instance, according to a studypublished in the Indian Journal of Anesthesia, 2018, the cases of mild,moderate, and severe spinal anesthesia induced hypotension was approximately 20%,35%, and 40% respectively.
Global Ephedrine Market –Competitive Landscape
Key player operating in themarket include Servier, Merck Sharp & Dohme Corp., Amgen Inc., Sanofi S.A.,Avadel Pharmaceuticals, GlaxoSmithKline plc, Endo Pharmaceuticals plc, andAkorn Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3320
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
